Pherecydes Pharma Publishes Its Half-year 2021 Financial Results and Assesses Its Positive Development Momentum


  • Ramping up of compassionate treatments, with 36 sufferers handled with Pherecydes Pharma phages in 12 hospitals to date
  •  Availability of anti-S. Aureus phages within the framework of early get entry to application predicted by means of give up-2021, in line with the roadmap announced by means of the Company
  •  Resounding fulfillment of the IPO completed at the start of the primary 1/2 of the year: cash function of €7.7 million at June 30, 2021
  • Videoconference with Guy-Charles Fanneau de La Horie at 10 am CEST these days

  Pherecydes Pharma (FR0011651694 – ALPHE), a biotechnology organization gaining practical experience in accuracy phage treatment to treat safe and additionally muddled bacterial diseases, today reports its monetary outcomes for the main portion of the year to June 30, 2021 and evaluates its exercises and advancement possibilities.

Uy-Charles Fanneau de La Horie, Chairman of the Executive Board of Pherecydes Pharma, says: “The first half of of 2021 turned into marked by using the strengthening of our economic.We have as a result improved our improvement plan and strengthened our groups with the recruitment of 10 new individuals of group of workers. This structuring of the company has enabled us to provide a reaction to the growing call for for our products in the framework of compassionate remedy, to put together our PhagoDAIR clinical examine, to report a dossier inquiring for early get admission to program (AAC)1 for our anti-Staphylococcus aureus phages and to accompany the PhagoPied (treatment of S. Aureus contamination of diabetic foot ulcers) and PhagOS (treatment of S. Aureus osteoarticular contamination of hips and knee prostheses) scientific studies. To date, 36 sufferers have benefited from compassionate remedy permitted through the ANSM (French Health government) with our anti-Staphylococcus aureus or anti-Pseudomonas aeruginosa phages, in diverse indicators and with different routes of administration. We have also been able to make sure the production, according with GMP (Good Manufacturing Practice), of numerous batches of phages that can be used inside the framework of AAC and clinical research”.

In the first 1/2 of 2021, general working profits, basically consisting of capitalized production related to the Staphylococcus aureus (S. Aureus) and Pseudomonas aeruginosa (P. Aeruginosa) packages, was €1,328 thousand in comparison with €422 thousand within the first half of of 2020, an increase of 215%. This distinction changed into a result of the enormous paintings undertaken in 2021 on these property, whilst inside the first half of 2020 activity were impacted by using the COVID-19 pandemic and greater cross-commercial enterprise work not as a consequence of those two property.

Pherecydes Pharma Publishes
  • Operating charges totaled €three,257 thousand inside the first 1/2 of 2021, up 27% in comparison with the determine of €2,568 thousand recorded a year earlier. This increase changed into due to a 24% rise in other purchases and outside charges and a 35% upward push in personnel charges following the strengthening of the groups at the Romainville and Nantes sites. The running loss changed into €1,929 thousand within the first half of 2021 as opposed to €2,146 thousand within the first half of of 2020, there has been therefore a ten% discount inside the operating loss. This development become ordinarily because of the large increase in running income between those intervals extra than offsetting the growth in working costs.

Exceptional profits totaled €225 thousand within the first 1/2 of 2021 versus €546 thousand inside the same half of of the preceding 12 months, reflecting the leveling out of spending within the framework of the PhagoProd challenge financed by the European Commission, on the way to soon be completed, and an high-quality provision booked for gadget the Company now not uses. The net loss turned into €1,454 thousand for the first six months of 2021, a mild lower compared with the lack of €1,527 thousand recorded over the identical period of 2020.

Financial structure At June 30, 2021, the Company had a cash role of €7,675 thousand (versus €1,652 thousand at December 31, 2020), a figure that appreciably consists of the €7 million net proceeds of the IPO achieved in February 2021. Shareholders’ equity was €10,942 thousand at June 30, 2021 versus €5,285 thousand at December 31, 2020. The Company’s cutting-edge cash role will permit Pherecydes Pharma to finance its improvement according with the method presented at the time of its IPO.

H1 2021 features and most recent attributes

  • Conceding of a €2 million State-Guaranteed Loan

On April 29, 2021, the Company reported that it had gotten, inside the system of the “State-Guaranteed Loan – Innovation Support” conspire, a €2 million advance from Bpifrance.

Pherecydes Pharma has likewise gotten the “Les Excellence” grant from Bpifrance for the blast course it has executed in 2021, representing Bpifrance’s unmistakable guide for the Compan.

  • Granting of a new patent in Hong Kong

Thanks to its energetic highbrow belongings coverage, Pherecydes Pharma has a portfolio of four patents overlaying every of its phages and their versions, some of that have already been granted in predominant jurisdictions inclusive of america, Europe, Japan, Australia, Hong Kong and Israel.

Testimony from a number of dealt with sufferers illustrates the real want for precision phage therapy, Pherecydes Pharma’s raison d’être and conflict, including the testimony posted in the Hospices Civils de Lyon newsletter.

  • Publications and medical meetings

On May 6, 2021, the Company announced the ebook, in Frontiers in Medicine by Prof. Tristan Ferry of Hospices Civils de Lyon, of an editorial highlighting the useful effect of the anti-Pseudomonas aeruginosa phages developed by using Pherecydes Pharma in treating a case of prosthetic knee infection. On June 7, 2021, the Company announced the book, in the prestigious British Journal of Pharmacology, of the results of a preclinical trial, in pigs, showing the blessings of inhaled.

This facts opens a brand new scope of utility for the belongings advanced with the aid of the Company.

  • Production of GMP batches

Pherecydes Pharma has endured the GMP (Good Manufacturing Practices) manufacturing of batches of phages with its numerous subcontractors. The Company now has GMP batches of anti-S. Aureus and anti-P. Aeruginosa phages.

Trategy & Outlook 

Over the coming months, the Company intends to keep the improvement of its various property and boost up the ramping up of precision phage therapy. The Company’s financial resources will extensively be allotted to accomplishing the subsequent strategic objectives:
 Download Report

Pherecydes Pharma Publishes Its Half-year 2021 Financial Results

About Pherecydes Pharma

Founded in 2006, Pherecydes Pharma is a biotechnology corporation that develops treatments towards resistant bacterial infections, responsible for many excessive infections. The Company has advanced an current method, precision phage remedy, based totally mostly on the use of phages, natural bacteria-killing viruses. Pherecydes Pharma is developing a portfolio of phages targeting 3 of the most resistant and dangerous micro organism, which by myself account for extra than thirds of health facility-acquired.The idea of precision phage remedy has been successfully done in numerous dozen patients within the context of compassionate use, underneath the supervision of the French National Agency for the Safety of Medicines (ANSM). 


This press launch consists of non-factual factors, inclusive of, but not confined to, positive statements regarding future outcomes and other destiny activities. These statements are primarily based at the modern vision and assumptions of the management of the Company. They comprise recognized and unknown dangers and uncertainties that might bring about sizeable variations in consequences, profitability and expected activities. In addition, Pherecydes Pharma, its shareholders and its associates, directors, officers, counsels and employees have not verified the accuracy of, and make no representations or warranties about, statistical data or forecast statistics contained within this information launch and that originates or is derived from 1/3 birthday celebration resources or enterprise courses; these statistical data and forecast statistics are simplest used in this press launch for statistics functions. Finally, this press release can be drafted in French and in English. In the occasion of differences between the 2 texts, the French version will be successful.